A real world, all comer, prospective, muLticenter, Clinical study to evaluate tHe safety and performance of the Eternia -EveroliMus Eluting Coronary Stent SYstem (EEECSS-Eternia) implanted as a part of standard clinical practice in India-ALCHEMY - ALCHEMY

Innvolution Healthcare Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1.Patients with ages more than 18 years.
•2.Males or non-pregnant females.
•3.Patient or legally authorized representative (LAR) agrees to participation by signing the informed consent form.
•4.Patient with coronary artery disease undergoing percutaneous coronary intervention (PCI) with Eternia Everolimus Eluting Coronary Stent System only.

•1.Pregnant and lactating females.
•2.Patient treated with any other stent for coronary artery disease within 1 week.
•3.Patients with impaired renal functions having baseline serum creatinine >2.0mg/DL.
•4.Patients with active bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage.
•5.Patients with known hypersensitivity or allergies to aspirin, heparin, clopidogrel, ticlopidine, Everolimus or similar drugs, or any other analogue or derivative, cobalt, chromium, nickel, molybdenum or contrast media.
•6.Patients with life expectancy of less than 12 months.
•7.Participating in other clinical studies that may restrict the patient’s compliance with follow up for this study.
•8.Any other condition or reason that in opinion of investigator may restrict patient’s participation or compliance or inability to complete the study.

发起方

Innvolution Healthcare Private Limited